

# Bay 59-3074

## Catalog No: tcsc5806



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



### Specifications

**CAS No:**

406205-74-1

**Formula:**

$C_{18}H_{13}F_6NO_4S$

**Pathway:**

GPCR/G Protein

**Target:**

Cannabinoid Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 34$  mg/mL (75.00 mM)

**Observed Molecular Weight:**

453.36

## Product Description


Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist with  $K_i$  values of 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively. Orally active CB1 agonist in vivo.

target: CB1/CB2 receptor partial agonist.

$K_i$ : 48.3 and 45.5 nM (CB1 and CB2 receptors)

In vitro: analgesic, antihyperalgesic, and antiallodynic properties in rat models of acute and chronic pain. The reference concentration is 10  $\mu$ M. [1]

In vivo: administration of BAY 59-3074 (ED<sub>50</sub> value: 0.41 mg/kg). Orally active CB1 agonist in vivo. [2] BAY 59-3074 (0.3-3 mg/kg, p.o.) induce antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic. Antiallodynic efficacy of BAY 59-3074 (1 mg/kg, p.o.) in the spared nerve injury model was maintained after 2 weeks of daily administration. However, tolerance developed rapidly (within 5 days) for cannabinoid-related side effect. [1] BAY 59-3074 have analgesic, antihyperalgesic, and antiallodynic properties in rat models of acute and chronic pain.[1]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!